German-general practioner-lantus-insulin-study: German observational cohort siudy of basal support oral therapy with insulin glargine;Deutsche-Hausarzt-Lantus-Insulinstudie (DHLS): Anwendungsbeobachtung zur basal unterstützten oralen herapie mit insulin glargin

Diabetes und Stoffwechsel

Volumn 14, Issue 1, 2005, Pages 13-18

  Schreiber, Stephan A ^a   Schneider, K ^b   Schweitzer, M A ^b   Haak, T ^c  

^a Diabetologe DDG ^*  (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c Diabetes Zentrum Mergentheim   (Germany)

Author keywords

Development of body weight; Insulin glargine; Metabolic control; Observational cohort study; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MARKETING; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GERMANY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL COHORT STUDY; PRURITUS; RASH; SKIN ALLERGY; SUPPLEMENTATION;

EID: 13844275359     PISSN: 09420037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. King H, Aubert RE, Hermman W: Global burden of diabetes 1995-2025. Diabetes Care 21 (1998) 1414-1431
2. Hauner H, Köster I, von Ferber L: Prävalenz des Diabetes mellitus in Deutschland 1998-2001. Dtsch. Med. Wochenschr. 128 (2003) 2632-2638
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
4. Chehade JM, Mooradian AD: A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 60 (2000) 95-113
5. Rosenstock J, Schwartz SL, Clark Jr CM et al.: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 23 (2001) 631-636
6. Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS: Issue relating to the early or earlier use of insulin in type 2 diabetes. Pract. Diab. Int. 20 (2003) 63-71
7. Riddle MC, Rosenstock J, Gerich J: The Treat-to-Target Trial. Diabetes Care 26 Vol. 11 (2003) 3080-3086
8. Fritsche A, Schweitzer MA, Häring HU and the 4001 Study Group: Glimepiride with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Annals of internat. Medicine 138 (2003) 952-969
9. Yki-Järvinen H: Combination therapy with insulin and oral agents optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab. Res. Rev 18 (2002) 77-81
10. Yki-Järvinen H, Dressler A, Ziemen M: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 (8) (2000) 1130-1136
11. 1c, fasting glucose (FBG) and hypoglycaemia using insulin glargine versus NPH insulin: A meta-regression in type 2 diabetes. Diabetes Metab 29 (2003)4S 232, abs 2216
12. Standl E, Maxeiner S, Schweitzer MA: Morning versus bedtime insulin glargine in combination with glimepiride: no difference in incidence of nocturnal hypoglycemia in patients with type 2 diabetes. Diabetes 52 (2003) A134 abs 575-P
13. Hauner H: Insulin glargin - das erste lang wirkende Insulinanalogon. Deutsches Ärzteblatt 100 Vol. 46 (2003) 3022-3027
14. Janka H, Plewe G, Kliebe-Frisch Ch, Schweitzer MA, Yki-Järvienen H: Starting insulin for type 2 diabetes with insulin glargine added to oral agents vs twice-daily premixed insulin alone. Diabetes 53 (2004) A 130 548P
15. Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Cavaliere D, Di Nardo B, Greenfield S, Kaplan SH, Michele Sacco M, Tognoni G, Valentini M, Nicolucci A and for the QuED Study Group: The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients. Diabetes Care 24 (2001) 1870-1877
16. Mensing C, Boucher J, Cypress M, Weinger K, Mulcahy K, Barta P, Hosey G, Kopher W, Lasichak A, Lamb B, Mangan M, Norman J, Tanja J, Yauk L, Wisdom K, Adams C: National Standards for Diabetes Self-Management Education. Diabetes Care 27: 143S